Research Groups

Section of Molecular Pathology

Previous Publications - All Publications 2016-2012

1. Stewart B. W., Bray F., Forman D., Ohgaki H., Straif K., Ullrich A., Wild C. P. (2016) Cancer prevention as part of precision medicine: 'plenty to be done' Carcinogenesis; 37(1):2-9. PMID: 26590901

2. Oh J.E., Ohta T., Satomi K., Foll M., Durand G., McKay J., Le Calvez-Kelm F., Mittelbronn M., Brokinkel B., Paulus W., Ohgaki H. (2015) Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas ; 74(10):952-959. PMID: 26360373

3. Xu Q.F., Pan Y.W., Li L.C., Zhou Z., Huang Q.L., Pang J.C., Zhu X.P., Ren Y., Yang H., Ohgaki H., Lv S.Q. (2014) MiR-22 is Frequently Downregulated in Medulloblastomas and Inhibits Cell Proliferation via the Novel Target PAPST1 Brain Pathology; 24(6):568-583.

4. Suzuki A., Nobusawa S., Natsume A., Suzuki H., Kim Y.H., Yokoo H., Nagaishi M., Ikota H., Nakazawa T., Wakabayashi T., Ohgaki H., Nakazato Y. (2014) Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas Journal of Neuro-Oncology; 120(2):283-291.

5. Peng C., Deng Q., Li Z., Xiong C., Li C., Zheng F. (2014) Risk-Association of DNMT1 Gene Polymorphisms with Coronary Artery Disease in Chinese Han Population International Journal of Molecular Sciences; 15(12):22694-22705.

6. Ohta T., Kim Y.H., Oh J.E., Satomi K., Nonoguchi N., Keyvani K., Pierscianek D., Sure U., Mittelbronn M., Paulus W., Vital A., Yokoo H., McDonald K., Kleihues P., Nazaret N., Barbet F., Lachuer J., Ohgaki H. (2014) Alterations of the RRAS and ERCC1 Genes at 19q13 in Gemistocytic Astrocytomas Journal of Neuropathology and Experimental Neurology; 73(10):908-915.

7. Ohgaki H., Burger P., Kleihues P. (2014) Definition of primary and secondary glioblastoma--response Clinical Cancer Research; 20(7):2013.

8. Louis D.N., Perry A., Burger P., Ellison D.W., Reifenberger G., von Deimling A., Aldape K., Brat D., Collins V.P., Eberhart C., Figarella-Branger D., Fuller G.N., Giangaspero F., Giannini C., Hawkins C., Kleihues P., Korshunov A., Kros J.M., Beatriz Lopes M., Ng H.K., Ohgaki H., Paulus W., Pietsch T., Rosenblum M., Rushing E., Soylemezoglu F., Wiestler O., Wesseling P. (2014) International society of neuropathology-haarlem consensus guidelines for nervous system tumor classification and grading Brain Pathology; 24(5):429-435.

9. Kim Y.H., Ohta T., Oh J.E., Le Calvez-Kelm F., McKay J., Voegele C., Durand G., Mittelbronn M., Kleihues P., Paulus W., Ohgaki H. (2014) TP53, MSH4, and LATS1 Germline Mutations in a Family with Clustering of Nervous System Tumors American Journal of Pathology; 184(9):2374-2381.

10. Gheit T., Abedi-Ardekani B., Carreira C., Missad C.G., Tommasino M., Torrente M.C. (2014) Comprehensive analysis of HPV expression in laryngeal squamous cell carcinoma Journal of Medical Virology; 86(4):642-646.

11. Fiaschetti G., Abela L., Nonoguchi N., Dubuc A.M., Remke M., Boro A., Grunder E., Siler U., Ohgaki H., Taylor M.D., Baumgartner M., Shalaby T., Grotzer M.A. (2014) Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activity and poor prognosis of medulloblastoma British Journal of Cancer; 110(3):636-647.

12. Corbex M., Bouzbid S., Traverse-Glehen A., Aouras H., McKay-Chopin S., Carreira C., Lankar A., Tommasino M., Gheit T. (2014) Prevalence of papillomaviruses, polyomaviruses, and herpesviruses in triple-negative and inflammatory breast tumors from algeria compared with other types of breast cancer tumors PloS One; 9(12):e114559.

13. Baumgarten P., Harter P.N., Tonjes M., Capper D., Blank A.E., Sahm F., von Deimling A., Kolluru V., Schwamb B., Rabenhorst U., Starzetz T., Kogel D., Rieker R.J., Plate K.H., Ohgaki H., Radlwimmer B., Zornig M., Mittelbronn M. (2014) Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity ; 40(2):205-216.

14. Wozniak M.B., Le Calvez-Kelm F., Abedi-Ardekani B., Byrnes G., Durand G., Carreira C., Michelon J., Janout V., Holcatova I., Foretova L., Brisuda A., Lesueur F., McKay J., Brennan P., Scelo G. (2013) Integrative genome-wide gene expression profiling of clear cell renal cell carcinoma in Czech Republic and in the United States ; 8(3):e57886.

15. Sasaki A., Yokoo H., Tanaka Y., Homma T., Nakazato Y., Ohgaki H. (2013) Characterization of microglia/macrophages in gliomas developed in S-100beta-v-erbB transgenic rats Neuropathology; 33(5):505-514.

16. Pierscianek D., Kim Y.H., Motomura K., Mittelbronn M., Paulus W., Brokinkel B., Keyvani K., Wrede K., Nakazato Y., Tanaka Y., Mariani L., Vital A., Sure U., Ohgaki H. (2013) MET gain in diffuse astrocytomas is associated with poorer outcome Brain Pathology; 23(1):13-18.

17. Ohgaki H., Kleihues P. (2013) The definition of primary and secondary glioblastoma Clinical Cancer Research; 19(4):764-772.

18. Ohgaki H. (2013) Contribution of Molecular Biology to the Classification of Low-Grade Diffuse Glioma ; 61-72.

19. Nonoguchi N., Ohta T., Oh J.E., Kim Y.H., Kleihues P., Ohgaki H. (2013) TERT promoter mutations in primary and secondary glioblastomas Acta Neuropathologica; 126(6):931-937.

20. Motomura K., Mittelbronn M., Paulus W., Brokinkel B., Keyvani K., Sure U., Wrede K., Nakazato Y., Tanaka Y., Nonoguchi N., Pierscianek D., Kim Y.H., Mariani L., Vital A., Perry A., Ohgaki H. (2013) PDGFRA gain in low-grade diffuse gliomas Journal of Neuropathology and Experimental Neurology; 72(1):61-66.

21. Nagaishi M., Paulus W., Brokinkel B., Vital A., Tanaka Y., Nakazato Y., Giangaspero F., Ohgaki H. (2012) Transcriptional factors for epithelial-mesenchymal transition are associated with mesenchymal differentiation in gliosarcoma Brain Pathology; 22(5):670-676.

22. Nagaishi M., Kim Y.H., Mittelbronn M., Giangaspero F., Paulus W., Brokinkel B., Vital A., Tanaka Y., Nakazato Y., Legras-Lachuer C., Lachuer J., Ohgaki H. (2012) Amplification of the STOML3, FREM2, and LHFP Genes Is Associated with Mesenchymal Differentiation in Gliosarcoma American Journal of Pathology; 180(5):1816-1823.

23. Motomura K., Mittelbronn M., Paulus W., Brokinkel B., Keyvani K., Sure U., Wrede K., Nakazato Y., Tanaka Y., Pierscianek D., Kim Y.H., Mariani L., Vital A., Ohgaki H. (2012) DMBT1 Homozygous Deletion in Diffuse Astrocytomas Is Associated With Unfavorable Clinical Outcome Journal of Neuropathology and Experimental Neurology; 71(8):702-707.

24. Lv S.Q., Kim Y.H., Giulio F., Shalaby T., Nobusawa S., Yang H., Zhou Z., Grotzer M., Ohgaki H. (2012) Genetic Alterations in MicroRNAs in Medulloblastomas Brain Pathology; 22(2):230-239.

25. Kim Y.H., Nonoguchi N., Paulus W., Brokinkel B., Keyvani K., Sure U., Wrede K., Mariani L., Giangaspero F., Tanaka Y., Nakazato Y., Vital A., Mittelbronn M., Perry A., Ohgaki H. (2012) Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss Brain Pathology; 22(6):834-840.

26. Badiali M., Gleize V., Paris S., Moi L., Elhouadani S., Arcella A., Morace R., Antonelli M., Buttarelli F.R., Figarella-Branger D., Kim Y.H., Ohgaki H., Mokhtari K., Sanson M., Giangaspero F. (2012) KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults Brain Pathology; 22(6):841-847.